Shares of AC Immune SA (ACIU) are currently gaining 35% on Thursday morning after the Switzerland-based clinical-stage biopharmaceutical company announced positive interim results from ongoing mid-stage trial in older patients with early Alzheimer's disease.
ACIU is currently trading at $9.91, up $2.60 or 35.57%, on the Nasdaq.
AC Immune announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its anti-phospho-Tau vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease.
ACI-35.030 vaccination, a collaboration with Janssen Pharmaceuticals of Johnson & Johnson (JNJ), generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels.
No clinically relevant adverse events were observed.
In September, AC Immune shares tanked after its mid-stage study evaluating Semorinemab in early alzheimer's disease failed to meet primary goals.
For comments and feedback contact: editorial@rttnews.com
